By Professor Leon Adams, Hepatologist and Dr Matthew Garas
Metabolic dysfunction-associated fatty liver disease (MAFLD) is now the most common liver condition in Australia and globally.
Previously termed non-alcoholic fatty liver disease (NAFLD), MAFLD is defined by hepatic steatosis in the presence of metabolic risk factors such as type 2 diabetes, overweight or obesity, dyslipidemia and hypertension.
The shift in nomenclature places greater emphasis on the underlying pathogenesis and recognises its potential to co-exist with additional liver risk factors such as alcohol excess....
Metabolic dysfunction-associated fatty liver disease (MAFLD) is now the most common liver condition in Australia and globally.
Previously termed non-alcoholic fatty liver disease (NAFLD), MAFLD is defined by hepatic steatosis in the presence of metabolic risk factors such as type 2 diabetes, overweight or obesity, dyslipidemia and hypertension.
The shift in nomenclature places greater emphasis on the underlying pathogenesis and recognises its potential to co-exist with additional liver risk factors such as alcohol excess....
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.